Characterization of a monoclonal antibody reactive with a subset of human breast tumors.
Fusion of spleen cells, from mice immunized against the human hormone-dependent breast cancer cell line ZR-75-1, with murine myeloma cells resulted in the establishment of a hybridoma cell line, HY59-H10 (H59). The purified monoclonal IgM produced by the hybridoma reacts with the most differentiated human breast tumor cell lines but not with cells derived from normal breast secretions or with numerous other malignant cell lines. Of 106 biopsy specimens examined, H59 bound to 54% of malignant breast specimens, to 83% of fibroadenomas, and to 82% of specimens containing fibrocystic disease.
D000232:Adenofibroma / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000276:immunology; D001706:Biopsy; D001943:Breast Neoplasms / Q000276:immunology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000276:immunology; D002460:Cell Line; D005069:Evaluation Studies as Topic; D005260:Female; D005348:Fibrocystic Breast Disease / Q000276:immunology; D006801:Humans
D000911:Antibodies, Monoclonal